You searched for: cetrorelix (Engelska - Maltesiska)

cetrorelix acetate
cetrorelix acetate

0.25 mg cetrorelix (as acetate).
0.25 mg cetrorelix (bħala acetate).

the active substance is cetrorelix acetate.
is-sustanza attiva hi cetrorelix acetate.

each vial contains 0.25 mg cetrorelix acetate.
kull kunjett fih 0.25 mg ta’ cetrorelix acetate.

each vial contains 0.25 mg cetrorelix (as acetate).
kull kunjett fih 0.25 mg ta’ cetrorelix (bħala acetate).

cetrotide 0.25 mg powder for solution for injection cetrorelix
cetrotide 0.25 mg trab għal soluzzjoni għall-injezzjoni cetrorelix

cetrotide contains a medicine called ‘cetrorelix acetate’.
cetrotide fih mediċina msejħa ‘cetrorelix acetate’.

cetrotide is a medicine that contains the active substance cetrorelix.
cetrotide huwa mediċina li fiha s-sustanza attiva cetrorelix.

cetrorelix competes with the binding of endogenous lhrh to these receptors.
cetrorelix jikkompeti ma’ l- għaqda ta’ lhrh endoġeni għal dawn ir-riċetturi.

cetrorelix is a luteinising hormone releasing hormone (lhrh) antagonist.
cetrorelix hu antagonist tal-ormon li jistimula l-produzzjoni tal-ormon ta’ lutejinazzazzjoni (lhrh).

the absolute bioavailability of cetrorelix after subcutaneous administration is about 85%.
il-mod assolut ta’ kif jinfirex fil-ġisem cetrorelix mogħti taħt il-ġilda hu ta’ madwar 85%.

cetrorelix showed no mutagenic or clastogenic potential in gene and chromosome mutation assays.
cetrorelix ma wera l-ebda potenzjal mutaġeniku jew klastoġeniku f’analiżi tal-ġeni u ta’ mutazzjoni ta’ kromożomi.

this ensures a delivery to the patient of a dose of at least 0.23 mg cetrorelix.
dan jassigura li l- pazjent jingħata doża ta ’ mill- anqas 0. 23 mg cetrorelix.

after reconstitution with the solvent provided, the concentration of cetrorelix is 1 mg/ ml.
wara t- taħlita mas- solvent provdut, il- konċentrazzjoni ta ’ cetrorelix hi ta ’ 1 mg/ ml.

following a single dose of 3 mg of cetrorelix a duration of action of at least 4 days has been evaluated.
wara doża waħda ta ’ 3mg cetrorelix, kien hemm perjodu ta ’ azzjoni ta ’ mill - inqas erbat ijiem.

studies in animals have indicated that cetrorelix exerts a dose related influence on fertility, reproductive performance and pregnancy.
studji fuq annimali indikaw li cetrorelix jeżerċita influwenza fuq il-fertilità, kapaċità riproduttiva u tqala skont kemm tkun qawwija d-doża li tingħata.

in animals as well as in humans, the antagonistic hormonal effects of cetrorelix were fully reversible after termination of treatment.
fl-annimali kif ukoll fil-bnedmin, l-effetti ormonali antagonistiċi ta’ cetrorelix kienu kompletament riversibbli wara t-tmiem tal-kura.

no target organ toxicity could be observed from acute, subacute and chronic toxicity studies in rats and dogs following subcutaneous administration of cetrorelix.
l-ebda effett tossiku fl-organi li fuqhom jaħdem cetrorelix ma kien osservat minn studji dwar effett tossiku akut, bejn akut u kroniku, u kroniku fuq ġrieden u klieb wara amministrazzjoni għal taħt il- ġilda ta’ cetrorelix.

the subcutaneous administration of single doses (0.25 mg to 3 mg cetrorelix) and also daily dosing over 14 days show linear kinetics.
l-amministrazzjoni taħt il-ġilda ta’ doża waħda (0.25 mg sa 3 mg cetrorelix) u ta’ doża kuljum għal 14-il ġurnata turi kinetika linejari.

in acute toxicity studies in rodents non-specific toxic symptoms were observed after intraperitoneal administration of cetrorelix doses more than 200 times higher than the pharmacologically effective dose after subcutaneous administration.
fi studji dwar effett tossiku akut fuq annimali gerriema kienu osservati sintomi tossiċi mhux speċifiċi wara l-amministrazzjoni ġol-peritonew ta’ dożi ta’ cetrorelix ta’ 200 darba aktar mid-doża farmakoloġikament effettiva wara l-amministrazzjoni taħt il-ġilda.